Aspire Biopharma Holdings, Inc.
A biopharmaceutical company developing a sublingual (under-the-tongue) drug delivery platform that lets medications and supplements absorb quickly into the bloodstream, skipping the stomach and liver. Founded in 2021, it came to life when the earlier shell company PowerUp Acquisition Corp. merged with it in early 2025 and the combined business took the name Aspire. The name "Aspire" nods to ambition, though the company has never spelled out a story behind it—a small mystery fans of naming lore can chew on.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| Highbridge Capital Management, LLC | 13G/APassive | 0% | 78 | Aug 14, 2026 |
| GARY SHIRINYAN | 13GPassive | 7.7% | 99.9K | Aug 10, 2026 |
| Lance Friedman | 13G/APassive | 7.92% | 107.3K | Aug 6, 2026 |
| Rubenbauer Alois Ryan III | 13GPassive | 5% | 65.0K | Jul 2, 2026 |
| Ardsley Advisory Partners LP | 13G/APassive | 0% | 0 | May 13, 2026 |
| Ardsley Advisory Partners GP LLC | 13G/APassive | 0% | 0 | May 13, 2026 |
| Ardsley Partners I GP LLC | 13G/APassive | 0% | 0 | May 13, 2026 |
| Ardsley Partners Advanced Healthcare Fund, L.P. | 13G/APassive | 0% | 0 | May 13, 2026 |
| Ardsley Partners Fund II, L.P. | 13G/APassive | 0% | 0 | May 13, 2026 |
| Philip J. Hempleman | 13G/APassive | 0% | 0 | May 13, 2026 |